Introduction {#s1}
============

Asthma is one of the most prevalent chronic diseases in children and adolescents, affecting ∼10% of children and adolescents in the UK and USA \[[@C1]--[@C3]\]. Studies have shown that \>50% of 4--18-year-old patients with asthma remain symptomatic despite treatment with at least an inhaled corticosteroid (ICS) \[[@C1], [@C2]\]. For these patients, the first intervention is to improve patient education and self-management. This involves ensuring adherence to the prescribed treatment and optimal use of the device, and, where possible, confirming the avoidance of allergens and exposure to environmental pollutants and tobacco smoke. Should symptoms persist, step-up treatments may be considered. Treatment options include addition of a long-acting β~2~-agonist (LABA) and/or a leukotriene receptor antagonist (LTRA) to the maintenance treatment regimen and/or a further increase in the dose of ICS \[[@C4]\]. ICS therapy is shown to affect growth in children, particularly when administered in medium-to-high doses over an extended period of time; thus, an alternative to increasing the ICS dose would be attractive \[[@C5], [@C6]\]. Common side-effects associated with LABAs include increased heart rate, palpitations and tremor, although tremor commonly resolves after the first few doses \[[@C7]\]. The LTRA montelukast has generally been regarded as safe for use in children, although inferior to ICS in terms of efficacy \[[@C8]\]. Conversely, a study utilising the Swedish database for adverse drug reactions, SWEDIS, which investigated drug groups commonly used in children, has shown that montelukast was the drug with the most frequent adverse drug reactions in 2005. The majority of these were in children \<5 years old and were predominately psychiatric in nature \[[@C9]\]. Another study has also highlighted some specific neuropsychiatric adverse events (AEs), of which users should be cognisant \[[@C10]\]. Therefore, there is an unmet need for more well-tolerated and efficacious therapeutic options for the treatment of paediatric patients with symptomatic asthma.

Tiotropium Respimat (Boehringer Ingelheim, Ingelheim am Rhein, Germany) (hereafter referred to as "tiotropium") is a long-acting muscarinic antagonist. It has been evaluated as an add-on therapy in a comprehensive phase 2 and 3 clinical trial programme including more than 6000 adult and paediatric patients with symptomatic asthma \[[@C11]--[@C24]\]. Based on the evidence from these trials, tiotropium is an efficacious add-on therapy, with safety and tolerability comparable with placebo in the individual studies. Tiotropium is indicated for once-daily use in the European Union (two inhalations of 2.5 µg) and USA (two inhalations of 1.25 µg) as maintenance treatment in patients with severe asthma aged ≥6 years \[[@C25], [@C26]\]. In addition to the safety reports of tiotropium add-on therapy from the individual clinical trials, and an in-depth, systematic assessment of safety and tolerability in adult patients \[[@C27], [@C28]\], the analysis presented here, involving a large sample of paediatric patients, can provide greater power to detect any as-yet unidentified safety signals, and allows the analysis of safety in subgroups that is impractical with individual trials.

The aim of the current analysis, therefore, was to further assess the safety and tolerability of tiotropium from a pooled population of paediatric (1--17 years) patients with symptomatic asthma at different Global Initiative for Asthma (GINA) treatment steps, and to investigate the seasonality of AEs relating to asthma exacerbations and symptoms in the pooled populations.

Methods {#s2}
=======

This pooled analysis included all phase 3 parallel-group studies in children (6--11 years) and adolescents (12--17 years), as well as a phase 2/3 study in children aged 1--5 years, included in the clinical development programme of tiotropium in asthma. All trials were of randomised, double-blind, placebo-controlled design, and between 12 weeks and 1 year in duration ([table 1](#TB1){ref-type="table"}) \[[@C18], [@C19], [@C21]--[@C23]\]. The treatment history (treatment step on enrolment) specified in each trial differed and reflected the severity of the patient population ([table 1](#TB1){ref-type="table"}).

###### 

Overview of study designs and key inclusion/exclusion criteria

                                                                                                                                               **NinoTinA-asthma \[[@C23]\]**                                                                                                                                              **CanoTinA-asthma \[[@C21]\]**                                                                                                                                                                        **VivaTinA-asthma \[[@C20]\]**                                                                                                                                                                 **RubaTinA-asthma \[[@C17]\]**                                                                                                                                                                  **PensieTinA-asthma \[[@C18]\]**
  ------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **[ClinicalTrials.gov](https://clinicaltrials.gov/) identifier**                                                                                      NCT01634113                                                                                                                                                                 NCT01634139                                                                                                                                                                                           NCT01634152                                                                                                                                                                                    NCT01257230                                                                                                                                                                                      NCT01277523
  **Phase and design^\#^**                                                                                                                               Phase 2/3                                                                                                                                     Phase 3, randomised, double-blind, placebo-controlled, parallel-group                                                                                                                                 Phase 3, randomised, double-blind, placebo-controlled, parallel-group                                                                                                                          Phase 3, randomised, double-blind, placebo-controlled, parallel-group                                                                                                                            Phase 3, randomised, double-blind, placebo-controlled, parallel-group
  **Objectives**                                                                                                                                    Efficacy and safety                                                                                                                                                         Efficacy and safety                                                                                                                                                                                   Efficacy and safety                                                                                                                                                                            Efficacy and safety                                                                                                                                                                              Efficacy and safety
  **Patient population**                                                                                                             1--5-year-olds with persistent asthmatic symptoms                                                                                                                            6--11-year-olds with symptomatic moderate asthma                                                                                                                                                       6--11-year-olds with symptomatic severe asthma                                                                                                                                               12--17-year-olds with symptomatic moderate asthma                                                                                                                                                 12--17-year-olds with symptomatic severe asthma
  **History of asthma**                                                                                                                                      NA                                                                                                                                                                      ≥6 months                                                                                                                                                                                             ≥6 months                                                                                                                                                                                      ≥3 months                                                                                                                                                                                        ≥3 months
  **Symptomatic asthma**                                                           Daytime symptoms more than twice a week; any limitation of activities; any nocturnal symptoms/awakenings; need for rescue medication \>2 days·week^−1^                                                                                           ACQ-IA ≥1.5                                                                                                                                                                                           ACQ-IA ≥1.5                                                                                                                                                                                      ACQ ≥1.5                                                                                                                                                                                         ACQ ≥1.5
  **Minimum asthma controller medication**                                                                             Stable ICS, with or without another controller, for ≥4 weeks before screening                                        Medium-dose ICS (200--400 μg·day^−1^ budesonide or equivalent dose), with or without another controller, for ≥4 weeks before screening; LABA had to be discontinued ≥24 h prior to screening   High-dose ICS (\>400 μg·day^−1^ budesonide or equivalent dose) plus ≥1 controller or medium-dose ICS (200--400 μg·day^−1^ budesonide or equivalent dose) plus ≥2 controllers for ≥4 weeks before screening   Medium-dose ICS (400--800 μg·day^−1^ budesonide or equivalent dose), with or without LTRA, for ≥4 weeks before screening; LABA had to be discontinued ≥72 h prior to screening   High-dose ICS (800--1600 μg·day^−1^ budesonide or equivalent dose) plus ≥1 controller or medium-dose ICS (400--800 μg·day^−1^ budesonide or equivalent dose) plus ≥2 controllers for ≥4 weeks before screening
  **Pre-bronchodilator FEV**~**1**~ **% pred at screening**                                                                                         ≤90% for 5-year-olds                                                                                                                                                              60--90%                                                                                                                                                                                               60--90%                                                                                                                                                                                        60--90%                                                                                                                                                                                          60--90%
  **FEV**~**1**~ **reversibility at screening**                                                                                                                                                                                                                                                                       ≥12%, 15--30 min after 200 μg salbutamol                                                                                                                                                              ≥12%, 15--30 min after 200 μg salbutamol                                                                                                                        ≥12% and ≥200 mL, 15--30 min after 400 μg salbutamol (age \>14 years) or ≥12% only (age 12--14 years)                                                                                            ≥12% and ≥200 mL, 15--30 min after 400 μg salbutamol (age \>14 years) or ≥12% only (age 12--14 years)
  **Variability of absolute FEV**~**1**~ **from screening to randomisation^¶^**                                                                                                                                                                                                                                                         ±30%                                                                                                                                                                                                  ±30%                                                                                                                                                                                           ±30%                                                                                                                                                                                             ±30%
  **Smoking history**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Nonsmoker or ex-smoker who stopped smoking ≥1 year prior to enrolment                                                                                                                            Nonsmoker or ex-smoker who stopped smoking ≥1 year prior to enrolment
  **Exclusion criteria**                                                                                                                   Significant disease other than asthma                                                                                                                                       Significant disease other than asthma                                                                                                                                                                 Significant disease other than asthma                                                                                                                                                          Significant disease other than asthma                                                                                                                                                            Significant disease other than asthma
  **Treatment**                                                                                                                      Once-daily tiotropium (5 or 2.5 µg) or placebo^+^                                                                                                                             Once-daily tiotropium (5 or 2.5 µg) or placebo                                                                                                                                                        Once-daily tiotropium (5 or 2.5 µg) or placebo                                                                                                                                                 Once-daily tiotropium (5 or 2.5 µg) or placebo                                                                                                                                                   Once-daily tiotropium (5 or 2.5 µg) or placebo
  **Treatment duration**                                                                                                                                  12 weeks                                                                                                                                                                    48 weeks                                                                                                                                                                                              12 weeks                                                                                                                                                                                       48 weeks                                                                                                                                                                                         12 weeks
  **Sample size**                                                                                                        102 randomised patients (101 treated, 102 planned); 101 completed patients                                                                                                  403 randomised patients (401 treated, 385 planned); 384 completed patients                                                                                                                            401 randomised patients (400 treated, 375 planned); 392 completed patients                                                                                                                398 randomised patients (397 treated, 127 planned per group); 376 completed patients                                                                                                                  392 randomised patients (392 treated, 375 planned); 388 completed patients

NA: not applicable; ACQ: Asthma Control Questionnaire; IA: interviewer-administered; ICS: inhaled corticosteroid; LTRA: leukotriene receptor antagonist; LABA: long-acting β~2~-agonist; FEV~1~: forced expiratory volume in 1 s; % pred: % predicted. ^\#^: note that NinoTinA-asthma was a phase 2/3 trial; ^¶^: the study allowed variation of absolute FEV~1~ values for visit 1 (pre-bronchodilator) compared with visit 2 (pre-dose) within ±30%; ^+^: in the NinoTinA-asthma study, patients aged 1--4 years at visit 1 were required to use an Aerochamber Plus Flow-Vu valved holding chamber (commonly referred to as a spacer) with a face mask for the inhalation of trial medication to reduce variability and ensure standardised dosing, whereas children aged 5 years at visit 1 were permitted to use the Respimat without a spacer (overall three patients did not use a spacer).

Trial medication {#s2a}
----------------

During the treatment period in all trials, patients received tiotropium (5 or 2.5 µg) or placebo (delivered by a Respimat inhaler as two puffs) once daily. Tiotropium was administered as add-on therapy to ICS maintenance treatment with or without other controller therapies. In the NinoTinA-asthma study \[[@C23]\], patients aged 1--4 years at screening were required to use an Aerochamber Plus Flow-Vu valved holding chamber (commonly referred to as a spacer; Trudell Medical International, London, ON, Canada) with a face mask for the inhalation of trial medication. Children aged 5 years at screening were permitted to use the Respimat with or without a spacer and mouthpiece, depending on preference.

End-points {#s2b}
----------

The assessment of safety (together with efficacy) was a primary objective in all five trials. In the four trials in children aged 6--17 years, the primary efficacy end-point was improvement in forced expiratory volume in 1 s and this is what the power calculations were based on. In the trial involving children aged \<6 years, there was no formal power calculation related to an end-point, but the recruitment was considered sufficient for the descriptive evaluation of efficacy and safety. This analysis is based on AEs occurring between first drug inhalation and until 30 days after the last dose of trial medication, coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 18.1 ([www.meddra.org](http://www.meddra.org)). Further details and definitions of AEs and serious AEs (SAEs) can be found in the [supplementary material](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01824-2018.figures-only#fig-data-supplementary-materials).

A composite end-point, grouping all AEs relating to the MedDRA-preferred term group "asthma exacerbations and asthma-related symptoms", from all studies in the pooled analysis was also analysed. Preferred terms included in this analysis are listed in [supplementary table E1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01824-2018.figures-only#fig-data-supplementary-materials).

Pooled safety data are presented for the following analysis groups: all patients, and subgroups by age, asthma severity and sex.

Additionally, the number of AEs related to asthma exacerbations and symptoms in the pooled data were plotted by month, with data from the Southern hemisphere shifted by 6 months to align the seasons (Northern hemisphere: June=month 6; Southern hemisphere: December=month 6).

Analyses were performed on the treated set, defined as all randomised patients who received at least one dose of trial medication. Analyses were evaluated descriptively and no inferential statistics were performed. Analysis of AEs related to asthma exacerbations and symptoms in the pooled data were plotted by month as a *post hoc* analysis and therefore considered exploratory only.

As has been reported, each study was conducted in accordance with the amended Declaration of Helsinki. The ethics research boards of the respective institutions approved the protocols, and signed, informed consent was obtained from all patients and/or their parents. See original publications for further details \[[@C18], [@C19], [@C21]--[@C23]\].

Results {#s3}
=======

A total of 1691 patients comprised the treated set ([table 2](#TB2){ref-type="table"}): 560 patients received tiotropium 5 µg, 559 patients received tiotropium 2.5 µg and 572 patients received placebo. Overall, the mean exposure to study medication was 314, 304 and 314 patient-years with tiotropium 5 µg, tiotropium 2.5 µg and placebo, respectively.

###### 

Overview of baseline demographics and disease characteristics: treated set

                                                                                      **NinoTinA-asthma \[[@C23]\]**   **CanoTinA-asthma \[[@C21]\]**   **VivaTinA-asthma \[[@C20]\]**   **RubaTinA-asthma \[[@C17]\]**   **PensieTinA-asthma \[[@C18]\]**
  ---------------------------------------------------------------------------------- -------------------------------- -------------------------------- -------------------------------- -------------------------------- ----------------------------------
  **Subjects**                                                                                     101                              401                              400                              397                               392
  **Male**                                                                                      61 (60.4)                        264 (65.8)                       279 (69.8)                       258 (65.0)                        242 (61.7)
  **Age years**                                                                                 3.0 (1--5)                      9.0 (6--11)                      9.0 (6--11)                     14.0 (11--17)                     14.0 (12--17)
  **Race**                                                                                                                                                                                                               
   White                                                                                        77 (76.2)                        339 (84.5)                       358 (89.5)                       368 (92.7)                        371 (94.6)
   Asian                                                                                        17 (16.8)                         10 (2.5)                         2 (0.5)                          13 (3.3)                          10 (2.6)
   Black/African-American                                                                        7 (6.9)                          7 (1.7)                          5 (1.3)                          14 (3.5)                          8 (2.0)
   American Indian/Alaska  Native                                                                   0                            45 (11.2)                         35 (8.8)                         2 (0.5)                           3 (0.8)
   Hawaiian/Pacific Islander                                                                        0                                0                                0                                0                                 0
  **Ethnicity**                                                                                                                                                                                                          
   Hispanic/Latino                                                                                  0                            55 (13.7)                        72 (18.0)                        42 (10.6)                         68 (17.3)
  **Never-smoker**                                                                                                                                                                                 396 (99.7)                        392 (100)
  **No exposure to second-hand smoke**                                                          92 (91.1)                        372 (92.8)                       369 (92.3)                       353 (88.9)                        367 (93.6)
  **Age at onset of asthma years**                                                               1.5±1.2                          4.7±2.4                          4.1±2.4                          6.5±4.1                           6.5±3.9
  **Duration of asthma years**                                                                1.3 (0.5--5.0)                  4.0 (0.5--11.0)                  4.8 (0.6--11.0)                  8.0 (0.3--16.3)                   8.0 (0.3--16.5)
  **Concomitant diagnoses**                                                                                                                                                                                              
   Allergic rhinitis                                                                            20 (19.8)                        230 (57.4)                       238 (59.5)                       219 (55.2)                        225 (57.4)
   Atopic dermatitis                                                                            17 (16.8)                        55 (13.7)                         38 (9.5)                         37 (9.3)                          38 (9.7)
  **FEV~1~ % pred**                                                                                                             84.06±10.79                      81.64±11.45                      82.79±10.56                       79.52±11.49
  **FEV~1~ % reversibility**                                                                                                    26.48±12.41                      27.43±13.43                      26.80±12.86                       29.19±14.26
  **ACQ score^\#^**                                                                                                              1.868±0.31                       1.966±0.36                       2.03±0.43                         2.13±0.43
  **Concomitant therapies at baseline**                                                                                                                                                                                  
   LTRAs                                                                                        41 (40.6)                        107 (26.7)                       339 (84.8)                        33 (8.3)                         315 (80.4)
   LABAs                                                                                         8 (7.9)                          1 (0.2)                         313 (78.3)                        1 (0.3)                          324 (82.7)
  **ICS dose of stable maintenance treatment μg·day^−1^ budesonide or equivalent**             255.2±187.4                      310.0±112.0                      457.4±236.0                      539.4±292.7                       747.0±357.7

Data are presented as n, n (%), median (range) or mean±[sd]{.smallcaps}. FEV~1~: forced expiratory volume in 1 s; % pred: % predicted; ACQ: Asthma Control Questionnaire; LTRA: leukotriene receptor antagonist; LABA: long-acting β~2~-agonist; ICS: inhaled corticosteroid. ^\#^: interviewer-administered ACQ in CanoTinA-asthma and VivaTinA-asthma.

Safety {#s3a}
------

The overall number of patients with AEs was generally comparable between treatment groups, including placebo ([table 3](#TB3){ref-type="table"}). Approximately half of the patients (n=879 (52%)) experienced at least one AE (n=283 (51%) receiving tiotropium 5 µg; n=286 (51%) receiving tiotropium 2.5 µg; n=310 (54%) receiving placebo). Very few AEs led to treatment discontinuation: two in patients receiving tiotropium 5 µg and five in patients receiving placebo. The only AE leading to discontinuation reported for more than one patient was asthma exacerbation/worsening (two patients receiving tiotropium 5 µg and two patients receiving placebo). The incidence of patients with investigator-defined drug-related AEs was low and comparable between treatment groups, including placebo. None of the drug-related AEs in the tiotropium treatment groups were serious or led to treatment discontinuation. The only AE assessed as drug related that was reported in more than two patients was cough (one patient receiving tiotropium 5 µg; one patient receiving tiotropium 2.5 µg; four patients receiving placebo). The overall frequency of patients that experienced SAEs was low and comparable between treatment groups. No SAEs were considered drug related or led to treatment discontinuation. The only SAEs reported for more than two patients were asthma exacerbation/worsening/crisis (five patients receiving tiotropium 5 µg; three patients receiving tiotropium 2.5 µg; five patients receiving placebo) and appendicitis (two patients receiving tiotropium 5 µg; two patients receiving tiotropium 2.5 µg; one patient receiving placebo). No deaths occurred during any of the trials.

###### 

Overview of patients reporting adverse events (AEs) in the pooled population: treated set (treatment plus 30 days following treatment)

                                                  **Tiotropium 5 µg**   **Tiotropium 2.5 µg**   **Placebo**
  ---------------------------------------------- --------------------- ----------------------- -------------
  **Subjects**                                            560                    559                572
  **Any AEs**                                         283 (50.5)             286 (51.2)         310 (54.2)
  **Drug-related AEs**                                  7 (1.3)                1 (0.2)            8 (1.4)
  **AEs leading to discontinuation**                    2 (0.4)                   0               5 (0.9)
  **Serious AEs**                                      10 (1.8)                8 (1.4)           13 (2.3)
  **AEs reported in ≥5% and ≥10 patients^\#^**                                                 
   Asthma exacerbation/worsening                      110 (19.6)             115 (20.6)         143 (25.0)
   Decreased peak expiratory flow rate                 55 (9.8)               64 (11.4)          68 (11.9)
   Nasopharyngitis/rhinopharyngitis                    44 (7.9)               46 (8.2)           49 (8.6)
   Viral respiratory tract infection                   27 (4.8)               24 (4.3)           30 (5.2)

Data are presented as n or n (%). Percentages are calculated using total number of patients per treatment as the denominator. ^\#^: in at least one treatment group.

Consistent with the disease profile, the most frequently reported AEs, reported by ≥5% of patients, were asthma exacerbation/worsening, decreased peak expiratory flow (PEF) rate, nasopharyngitis/rhinopharyngitis and viral respiratory tract infection ([table 3](#TB3){ref-type="table"}; AEs reported by ≥2% of patients are shown in [supplementary table E2](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01824-2018.figures-only#fig-data-supplementary-materials)). These were reported by a similar proportion of patients in the tiotropium and placebo groups, except asthma exacerbation/worsening, which was reported by fewer patients in the tiotropium treatment groups.

The frequency of patients reporting a composite end-point, grouping all AEs related to asthma exacerbations and asthma symptoms, was lower in the tiotropium treatment groups than with placebo (placebo: 217 patients with event (37.9%); tiotropium 5 µg: 177 patients with event (31.6%), rate ratio over placebo 0.76 (95% CI 0.63--0.93); tiotropium 2.5 µg: 195 patients with event (34.9%), rate ratio over placebo 0.87 (95% CI 0.72--1.05)). A description of safety topics of interest is available in the [supplementary material](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01824-2018.figures-only#fig-data-supplementary-materials).

Subgroups by age {#s3b}
----------------

Safety in the different age categories was generally comparable with the pooled population ([table 4](#TB4){ref-type="table"}). The lower proportion of patients with asthma exacerbation/worsening as an AE in the tiotropium groups compared with the placebo group was most prominently observed in patients aged 1--5 years (6.5% for tiotropium 5 µg; 13.9% for tiotropium 2.5 µg; 29.4% for placebo), with similar trends in patients aged 6--11 years (26.4% for tiotropium 5 µg; 25.5% for tiotropium 2.5 µg; 32.8% for placebo) and 12--17 years (14.4% for tiotropium 5 µg; 16.3% for tiotropium 2.5 µg; 16.8% for placebo).

###### 

Overview of patients reporting adverse events (AEs) by age subgroups: treated set (treatment plus 30 days following treatment)

                                               **Tiotropium 5 µg**   **Tiotropium 2.5 µg**   **Placebo**
  ------------------------------------------- --------------------- ----------------------- -------------
  **Age 1--5 years \[[@C23]\]**                                                             
   Subjects                                            31                     36                 34
   Any AEs                                          18 (58.1)              20 (55.6)          25 (73.5)
   Drug-related AEs                                  2 (6.5)                   0               2 (5.9)
   AEs leading to discontinuation                       0                      0                  0
   Serious AEs                                          0                      0               3 (8.8)
   AEs reported in ≥5% and ≥10 patients^\#^                                                 
    Asthma exacerbation/worsening                    2 (6.5)               5 (13.9)           10 (29.4)
  **Age 6--11 years \[[@C21], [@C22]\]**                                                    
   Subjects                                            265                    271                265
   Any AEs                                         138 (52.1)             145 (53.5)         155 (58.5)
   Drug-related AEs                                  1 (0.4)                   0               4 (1.5)
   AEs leading to discontinuation                    2 (0.8)                   0               2 (0.8)
   Serious AEs                                       5 (1.9)                5 (1.8)            8 (3.0)
   AEs reported in ≥5% and ≥10 patients^\#^                                                 
    Asthma exacerbation/worsening                   70 (26.4)              69 (25.5)          87 (32.8)
    Decreased peak expiratory flow rate             44 (16.6)              46 (17.0)          47 (17.7)
    Nasopharyngitis/rhinopharyngitis                18 (6.8)               21 (7.7)           24 (9.1)
  **Age 12--17 years \[[@C18], [@C19]\]**                                                   
   Subjects                                            264                    252                273
   Any AEs                                         127 (48.1)             121 (48.0)         130 (47.6)
   Drug-related AEs                                  4 (1.5)                1 (0.4)            2 (0.7)
   AEs leading to discontinuation                       0                      0               3 (1.1)
   Serious AEs                                       5 (1.9)                3 (1.2)            2 (0.7)
   AEs reported in ≥5% and ≥10 patients^\#^                                                 
    Asthma exacerbation/worsening                   38 (14.4)              41 (16.3)          46 (16.8)
    Nasopharyngitis/rhinopharyngitis                24 (9.1)               18 (7.1)           20 (7.3)
    Decreased peak expiratory flow rate             11 (4.2)               18 (7.1)           21 (7.7)
    Viral respiratory tract infection               11 (4.2)               11 (4.4)           14 (5.1)

Data are presented as n or n (%). Percentages are calculated using total number of patients per treatment as the denominator. ^\#^: in at least one treatment group.

No SAEs were reported in patients treated with tiotropium in the 1--5-year-old group and no AEs in this age group led to discontinuation in any treatment group ([table 4](#TB4){ref-type="table"}; SAEs by age are shown in [supplementary table E3](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01824-2018.figures-only#fig-data-supplementary-materials)). Asthma was the only AE preferred term reported in ≥5%, or in 10 or more patients, in any of the treatment groups.

An analysis of pooled data from studies with patients aged ≥6 years is detailed in [supplementary table E4](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01824-2018.figures-only#fig-data-supplementary-materials).

Subgroups by asthma severity {#s3c}
----------------------------

The safety in the different asthma severity categories was generally comparable with the pooled population ([table 5](#TB5){ref-type="table"}). However, compared with the pooled population, more patients with moderate asthma reported at least one AE and fewer patients with severe asthma reported at least one AE. This is most likely due to the longer duration of the studies in moderate asthma (48 weeks for moderate asthma *versus* 12 weeks for severe asthma). Of note, in patients with severe asthma, decreased PEF rate was reported by fewer patients in the tiotropium groups than in the placebo group.

###### 

Overview of patients reporting adverse events (AEs) in subgroups by asthma severity: treated set (treatment plus 30 days following treatment)

                                               **Tiotropium 5 µg**   **Tiotropium 2.5 µg**   **Placebo**
  ------------------------------------------- --------------------- ----------------------- -------------
  **Moderate asthma \[[@C18], [@C22]\]**                                                    
   Subjects                                            269                    260                269
   Any AEs                                         166 (61.7)             165 (63.5)         171 (63.6)
   Drug-related AEs                                  4 (1.5)                1 (0.4)            3 (1.1)
   AEs leading to discontinuation                       0                      0               2 (0.7)
   Serious AEs                                       4 (1.5)                5 (1.9)            8 (3.0)
   AEs reported in ≥5% and ≥10 patients^\#^                                                 
    Asthma exacerbation/worsening                   69 (25.7)              76 (29.2)          89 (33.1)
    Decreased peak expiratory flow rate             35 (13.0)              40 (15.4)          35 (13.0)
    Nasopharyngitis/rhinopharyngitis                31 (11.5)              28 (10.8)          30 (11.2)
    Viral respiratory tract infection               18 (6.7)               19 (7.3)           19 (7.1)
    Respiratory tract infection                     15 (5.6)               16 (6.2)           21 (7.8)
  **Severe asthma \[[@C19], [@C21]\]**                                                      
   Subjects                                            260                    263                269
   Any AEs                                          99 (38.1)             101 (38.4)         114 (42.4)
   Drug-related AEs                                  1 (0.4)                   0               3 (1.1)
   AEs leading to discontinuation                    2 (0.8)                   0               3 (1.1)
   Serious AEs                                       6 (2.3)                3 (1.1)            2 (0.7)
   AEs reported in ≥5% and ≥10 patients^\#^                                                 
    Asthma exacerbation/worsening                   39 (15.0)              34 (12.9)          44 (16.4)
    Decreased peak expiratory flow rate             20 (7.7)               24 (9.1)           33 (12.3)
    Nasopharyngitis/rhinopharyngitis                11 (4.2)               11 (4.2)           14 (5.2)

Data are presented as n or n (%). Percentages are calculated using total number of patients per treatment as the denominator. ^\#^: in at least one treatment group.

Subgroup analyses of LABA and LTRA use at randomisation were also performed; as expected, the results were consistent with the subgroup analyses by severity, since LABAs/LTRAs were predominantly taken by patients with more severe asthma.

Subgroups by sex {#s3d}
----------------

In an analysis of AEs by sex, there were fewer females than males in each treatment group; proportionally, slightly fewer females reported AEs compared with males, particularly in the tiotropium 5 µg and placebo groups, with no notable differences in the proportion of patients with drug-related AEs or AEs leading to discontinuation ([table 6](#TB6){ref-type="table"}). As in the overall analysis, the frequency of patients experiencing SAEs was low and comparable between treatment groups.

###### 

Overview of patients reporting adverse events (AEs) in subgroups by sex: treated set (treatment plus 30 days following treatment)

                                               **Tiotropium 5 µg**   **Tiotropium 2.5 µg**   **Placebo**
  ------------------------------------------- --------------------- ----------------------- -------------
  **Males**                                                                                 
   Subjects                                            365                    373                366
   Any AEs                                         195 (53.4)             190 (50.9)         201 (54.9)
   Drug-related AEs                                  5 (1.4)                   0               5 (1.4)
   AEs leading to discontinuation                    2 (0.5)                   0               3 (0.8)
   Serious AEs                                       7 (1.9)                6 (1.6)            4 (1.1)
   AEs reported in ≥5% and ≥10 patients^\#^                                                 
    Asthma exacerbation/worsening                   75 (20.5)              73 (19.6)          94 (25.7)
    Decreased peak expiratory flow rate             38 (10.4)              49 (13.1)          44 (12.0)
    Nasopharyngitis/rhinopharyngitis                29 (7.9)               34 (9.1)           34 (9.3)
    Viral respiratory tract infection               16 (4.4)               14 (3.8)           22 (6.0)
    Respiratory tract infection                     14 (3.8)               11 (2.9)           20 (5.5)
  **Females**                                                                               
   Subjects                                            195                    186                206
   Any AEs                                          88 (45.1)              96 (51.6)         109 (52.9)
   Drug-related AEs                                  2 (1.0)                1 (0.5)            3 (1.5)
   AEs leading to discontinuation                       0                      0               2 (1.0)
   Serious AEs                                       3 (1.5)                2 (1.1)            9 (4.4)
   AEs reported in ≥5% and ≥10 patients^\#^                                                 
    Asthma exacerbation/worsening                   35 (17.9)              42 (22.6)          49 (23.8)
    Decreased peak expiratory flow rate             17 (8.7)               15 (8.1)           24 (11.7)
    Nasopharyngitis/rhinopharyngitis                15 (7.7)               12 (6.5)           15 (7.3)
    Viral respiratory tract infection               11 (5.6)               10 (5.4)            8 (3.9)

Data are presented as n or n (%). Percentages are calculated using total number of patients per treatment as the denominator. ^\#^: in at least one treatment group.

Analysis of seasonal asthma worsening {#s3e}
-------------------------------------

When analysed by month, reports of AEs related to asthma exacerbations and symptoms were greatest in the placebo group in the spring, autumn and winter ([figure 1](#F1){ref-type="fig"}), and lowest in the summer. With both doses of tiotropium, spring and autumn peaks were reduced. An analysis by month of reported AEs relating to asthma exacerbations and symptoms from studies with patients aged ≥6 years is detailed in [supplementary figure E1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01824-2018.figures-only#fig-data-supplementary-materials).

![Number of reported adverse events (AEs) related to asthma exacerbations and symptoms over 12 months in the pooled population. a) Tiotropium 5 µg and placebo groups. b) Tiotropium 2.5 µg and placebo groups. Data from the Southern hemisphere shifted by 6 months to align the seasons (Northern hemisphere: June=month 6; Southern hemisphere: December=month 6).](ERJ-01824-2018.01){#F1}

Discussion {#s4}
==========

In this comprehensive pooled analysis, tiotropium was well tolerated, with a safety profile comparable with placebo. Specifically, the incidence of patients reporting drug-related AEs, AEs leading to discontinuation, SAEs and AEs commonly associated with anticholinergic therapy was low and generally balanced between treatment groups, including placebo. Baseline demographics and disease characteristics were comparable between the treatment groups within each trial ([table 2](#TB2){ref-type="table"}). Pharmacokinetic data from the 1--5-year-old group (including those using the valved holding chamber) have previously been shown to be comparable with results from 6--17-year-old groups when adjusted for body size, indicating adequacy of systemic exposure to tiotropium \[[@C29]\].

Efficacy data suggest that tiotropium is an effective add-on to ICS, with or without additional controller therapies, in children and adolescents with asthma \[[@C16]--[@C19], [@C22], [@C23]\]. The results of this pooled analysis provide additional evidence of the favourable safety profile of tiotropium in children and adolescents with symptomatic asthma (aged 1--17 years) \[[@C28], [@C29]\].

An important finding is that AEs related to asthma symptoms and exacerbations were reported by fewer patients in the tiotropium 5 µg treatment group compared with the placebo, with particular effect in reducing spring and autumn seasonal peaks. While reported as a safety parameter, this signal may also be considered in terms of efficacy, particularly in very young children with asthma, where validated tools for the assessment of efficacy in clinical trials are currently limited \[[@C23]\]. It is interesting to note that this effect with tiotropium added to ICS/LABA has been observed with other interventions, including ICS/LABA combinations \[[@C30]\] and biologicals \[[@C31]\]. As long-term asthma exacerbation trials in paediatric patients remain ethically challenging, this analysis highlights an alternative end-point to investigate such efficacy in children. These data also highlight the importance of trial timing to account for seasonal exacerbation peaks when a 12-month study length is not practical. However, since this finding is exploratory, it should be confirmed in a predefined study that could also investigate which age subgroup had the greatest benefit.

Reported class effects of anticholinergics include upper respiratory tract infections, tachycardia, dry mouth and other gastrointestinal complications, as well as urinary retention and urinary tract infections \[[@C32]--[@C35]\]. The incidence of patients reporting these AEs was low in the present analysis and, overall, the safety profile of tiotropium was comparable with placebo in all trials reported here \[[@C29]\]. Notably, cardiac events were reported by only two patients and they were both in the placebo group.

Within analyses of population subgroups defined by age, asthma severity, sex and LABA/LTRA use at baseline, the proportions of patients reporting AEs and SAEs were generally comparable between treatment groups, including placebo. This is further supported by a recent systematic review of the efficacy and safety of tiotropium in children aged 6--11 years with symptomatic moderate-to-severe asthma \[[@C36]\]. The authors concluded that none of the three studies included in the analysis (two of which are included in the analysis presented here) showed an increase in the rate of AEs or SAEs reported in the tiotropium group compared with placebo \[[@C36]\].

A major strength of this analysis is that all the trials were placebo controlled with comparable design and therefore provide the most valid comparison for assessing AEs. Furthermore, all patients continued to receive their usual maintenance therapies (except for LABA in patients with moderate asthma), allowing investigation of tiotropium in varied settings of concurrent medications and thereby making it as representative of treatment in a real-world setting as is achievable in a clinical trial setting. The patient sample was very large and covered a wide age range; patients were recruited from various populations and geographical locations, including a high proportion of Latin American patients (a population noted to have a high incidence and a higher severity of childhood asthma). Limitations of our pooled analysis included the difference in duration of the five included trials (two at 48 weeks and three at 12 weeks) and that none were \>48 weeks.

Conclusions {#s4a}
-----------

Once-daily tiotropium as add-on to at least ICS maintenance treatment in patients aged 1--17 years with symptomatic asthma at different GINA treatment steps is an addition to current treatment options, with a safety and tolerability profile comparable with that of placebo. No new safety signals were identified in this comprehensive analysis, which supports the favourable risk--benefit profile of once-daily tiotropium as add-on to maintenance ICS with or without additional controllers in paediatric patients with symptomatic asthma. Moreover, a reduction in patients reporting AEs related to asthma exacerbations and asthma symptoms was observed with tiotropium 5 µg, especially related to seasonal peaks in exacerbations.
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